Pharvaris stock surges 27% on positive trial data

Oppenheimer raised Pharvaris' (PHVS) price target to $75 from $50, citing positive clinical trial data for deucrictibant XR in hereditary angioedema prophylaxis. The stock is near its 52-week high, with a 61% return over the past year. Other firms also raised targets, highlighting regulatory progress and potential peak sales of $1.8 billion.

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Roivant Sciences (ROIV) and Pharvaris (PHVS) reached record highs after positive clinical trial results. Roivant's drug, mosliciguat, showed a 56.3% improvement in lung blood flow resistance over 16 weeks. Both companies' stocks surged on the news.

Pharvaris N.V. (PHVS) shares rose 15.55% to $40.73 after reporting positive Phase 3 study results for deucrictibant XR in preventing HAE attacks. The stock opened at $40.92 and has a 52-week range of $20.65-$43.25.

Pharvaris NV (PHVS) stock rose 12.4% after reporting positive Phase 3 trial results for deucrictibant XR, reducing hereditary angioedema attacks by 83% vs. placebo. The study met all endpoints, and the company plans regulatory submissions, including a U.S. filing in early 2027. PHVS shares hit a 52-week high of $43.25 before retreating slightly.

Pharvaris (PHVS) reported positive Phase 3 CHAPTER-3 study results for deucrictibant XR, showing an 83% reduction in HAE attack rates vs. placebo. All primary and secondary endpoints were met. The company plans to submit marketing applications in 2027. PHVS stock rose 22.5% premarket.